MiNK Therapeutics Statistics
Share Statistics
MiNK Therapeutics has 3.97M
shares outstanding. The number of shares has increased by 14.21%
in one year.
| Shares Outstanding | 3.97M |
| Shares Change (YoY) | 14.21% |
| Shares Change (QoQ) | 0.29% |
| Owned by Institutions (%) | 2.05% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,730 |
| FTD / Avg. Volume | 9.34% |
Short Selling Information
The latest short interest is 26.46K, so 0.67% of the outstanding
shares have been sold short.
| Short Interest | 26.46K |
| Short % of Shares Out | 0.67% |
| Short % of Float | 2.62% |
| Short Ratio (days to cover) | 4.71 |
Valuation Ratios
The PE ratio is -0.02 and the forward
PE ratio is -1.64.
MiNK Therapeutics's PEG ratio is
0.
| PE Ratio | -0.02 |
| Forward PE | -1.64 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | -13.43 |
| P/FCF Ratio | -27.52 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for MiNK Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.72,
with a Debt / Equity ratio of -0.25.
| Current Ratio | 0.72 |
| Quick Ratio | 0.72 |
| Debt / Equity | -0.25 |
| Debt / EBITDA | -0.47 |
| Debt / FCF | -0.52 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-468,904,434.78 |
| Employee Count | 23 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -10.77B |
| Effective Tax Rate | 99.9% |
Stock Price Statistics
The stock price has increased by -22.45% in the
last 52 weeks. The beta is 0.14, so MiNK Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.14 |
| 52-Week Price Change | -22.45% |
| 50-Day Moving Average | 8.29 |
| 200-Day Moving Average | 7.94 |
| Relative Strength Index (RSI) | 46.18 |
| Average Volume (20 Days) | 18,527 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | n/a |
| Net Income | -10.78B |
| EBITDA | -10.57M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -285.82 |
Full Income StatementBalance Sheet
The company has 4.58M in cash and 4.92M in
debt, giving a net cash position of -347.57K.
| Cash & Cash Equivalents | 4.58M |
| Total Debt | 4.92M |
| Net Cash | -347.57K |
| Retained Earnings | -144.18B |
| Total Assets | 5.72M |
| Working Capital | -1.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -9.56M
and capital expenditures 0, giving a free cash flow of -9.56M.
| Operating Cash Flow | -9.56M |
| Capital Expenditures | n/a |
| Free Cash Flow | -9.56M |
| FCF Per Share | -0.25 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
